Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma.

Drugs · 2025 · PMC12738588 · PMID 39820839

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

In addition, nominally significant median TUDD prolongations in the physical, role and emotional functioning, pain, dyspnoea and constipation EORTC QLQ-C30 subscales favouring NALIRIFOX over gemcitabine plus nab-paclitaxel were also seen (Sect. 2 ).

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.